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Abstract
To date there has been a focus on the application of sterically stabilized liposomes, composed of saturated
diacylphospholipid, polyethylene glycol (PEG) conjugated lipids (5^10 mole%) and cholesterol (CH) (s 30 mole%), for the
systemic delivery of drugs. However, we are now exploring the utility of liposome formulations composed of
diacylphospholipid conjugated PEG mixtures prepared in the absence of added cholesterol, with the primary objective
of developing formulations that retain encapsulated drug better than comparable formulations prepared with cholesterol.
In this report the stability of cholesterol-free distearoylphosphatidylcholine (DSPC):distearoylphosphatidylethanolamine
(DSPE)-PEG2000 (95:5 mol/mol) liposomes was characterized in comparison to cholesterol-containing formulations
DSPC:CH (55:45 mol/mol) and DSPC:CH:DSPE-PEG2000 (50:45:5 mol/mol/mol), in vivo. Circulation longevity of these
formulations was determined in consideration of variables that included varying phospholipid acyl chain length, PEG
content and molecular weight. The application of cholesterol-free liposomes as carriers for the hydrophobic anthracycline
antibiotic, idarubicin (IDA), was assessed. IDA was encapsulated using a transmembrane pH gradient driven process. To
determine stability in vivo, pharmacokinetic studies were performed using ‘empty’ and drug-loaded [3H]cholesteryl
hexadecyl ether radiolabeled liposomes administered intravenously to Balb/c mice. Inclusion of 5 mole% of DSPE-PEG2000
or 45 mole% cholesterol to DSPC liposomes increased the mean plasma area under the curve (AUC0ÿ24h) 19-fold and 10-
fold, respectively. Cryo-transmission electron micrographs of IDA loaded liposomes indicated that the drug formed a
precipitate within liposomes. The mean AUC0ÿ4h for free IDA was 0.030 Wmole h/ml as compared to 1.38 Wmole h/ml
determined for the DSPC:DSPE-PEG2000 formulation, a 45-fold increase, demonstrating that IDA was retained better in
cholesterol-free compared to cholesterol-containing liposomes. ß 2002 Elsevier Science B.V. All rights reserved.
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1. Introduction
Many drugs have shown improved therapeutic
properties when administered in a liposome encapsu-
lated form. This is a consequence of liposome medi-
ated changes in drug pharmacokinetics and biodistri-
bution that can (i) decrease toxicity and drug
metabolism and/or (ii) enhance cellular or tumor
drug delivery which, in turn, engenders improved
antitumor activity. The progressive success of lipid
carrier technology is re£ected by the approval of
various liposomal formulations of doxorubicin
(Myocet, Doxil) and daunorubicin (DaunoXome)
for human use [1^3]. The development of liposomes
as e¡ective drug delivery systems was achieved, in
part, as a consequence of improved properties ob-
tained following incorporation of membrane rigidify-
ing agents such as cholesterol. In fact, some of the
early research on liposomes as delivery systems for
i.v. applications demonstrated that the presence of
cholesterol (i) enhanced retention of entrapped sol-
utes [4^8], (ii) diminished interaction with serum pro-
teins [9,10], (iii) reduced phospholipid loss by phos-
pholipases and lipoproteins [11^13], (iv) reduced
macrophage digestion [14] and (v) maintained mem-
brane £uidity over a wide temperature range. It is
believed that a combination of these factors collec-
tively yielded lipid carriers that were resilient within
the biological milieu in terms of both liposome struc-
ture stability and retention of entrapped solutes.
Although neutral liposomes prepared of phospha-
tidylcholine species and cholesterol were e¡ective as
drug carriers, there remained perceived drawbacks to
the technology. In particular, the rapid elimination
of the liposomes following i.v. injection, an observa-
tion associated with liposome accumulation in the
mononuclear phagocytic system (MPS), was not fully
optimized. Although appropriately designed formu-
lations prepared of phospholipids and cholesterol did
provide substantial improvements in drug delivery to
diseased sites residing in non-MPS organs [15], it was
proposed that additional bene¢ts would be achieved
if the rate of liposome elimination could be reduced.
These conventional formulations, therefore, were
superseded by second generation liposomes termed
‘sterically stabilized’ or Stealth, that incorporate a
surface coating consisting of either a ganglioside
GM1 or synthetic neutral polymer polyethylene glycol
(PEG) [16,17]. These novel formulations signi¢cantly
advanced and broadened the application of choles-
terol-containing liposome formulations. In addition
to previously mentioned attributes of conventional
cholesterol-containing liposomes, sterically stabilized
liposomes exhibit signi¢cantly greater circulation
half-lives [18^21] and the elimination behavior of
these liposomes was no longer as sensitive to lipo-
somal lipid dose [22,23]. Subsequent studies illus-
trated that a longer circulation half-life could facil-
itate higher drug accumulation within sites of
tumor growth [24^26] and this was associated with
greater antitumor activity [27^29]. Furthermore, in-
corporation of PEG modi¢ed lipids has provided
£exibility in altering the liposome composition, while
maintaining the pharmacokinetic behavior of lipid
carriers and therefore we investigated the properties
of liposomes prepared in the absence of cholesterol
for the intended purpose of retaining entrapped
drugs.
Given the progress in liposome technology as de-
livery systems for anticancer drugs, some may ¢nd it
surprising that this simple methodology is not ap-
plied more generically to other cancer drugs. In prin-
ciple, liposomes must be developed with desirable
and controlled release properties that are selected
on the basis of the drug being entrapped. More spe-
ci¢cally, we argue that liposomal lipid composition
cannot be viewed in generic terms, where one lipo-
some formulation is suitable for all drugs. Rather it
is critical for the liposome to be designed around the
drug of interest. In our laboratory we determine the
suitability of a liposome formulation by an iterative
process which correlates pharmacodynamic behavior
of the encapsulated drug with the plasma elimination
and biodistribution behavior of the liposomal carrier.
A critical measured parameter obtained in these
studies is in vivo drug release rate which, in turn, is
critically dependent on lipid composition. It is well
understood that liposomal formulations prepared us-
ing zwitterionic lipids, such as diacylphosphatidyl-
choline, and cholesterol are e¡ective as drug carriers,
but the bene¢ts for a given anticancer drug depend
on their ability to retain drug following i.v. admin-
istration. Further, simple changes in phospholipid
acyl chain length can have dramatic e¡ects on in
vivo drug release rates [30]. In general, as acyl chain
length increases, drug retention increases [31]. There
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are some drugs, however, which are simply not re-
tained well in these phospholipid/cholesterol formu-
lations, even when the acyl chain length increases to
C22 and exhibit gel to liquid crystal transitions
above 100‡C. Another solution to improve drug re-
tention is based on preparation of liposomes without
cholesterol. This has not been explored thoroughly,
but there are now compelling reasons to consider the
potential of cholesterol-free liposomes as carriers. As
a direct consequence of cholesterol’s interactions
with phospholipids, the permeability of a liposome
increases at temperatures below the phase transition
temperature (Tc) of the bulk lipid component [32,33].
Thus, membranes (absent of cholesterol) consisting
of gel phase lipids (Tc s 40‡C) will form a more rigid
membrane capable of retaining contents for in vivo
administration. Additional incorporation of surface
stabilizing PEGs will further prevent surface^surface
interactions to facilitate prolonged circulation life-
times. To date little is known about the application
of cholesterol-free liposomes for retention of en-
trapped solutes and these reasons, alone, were su⁄-
cient to propose that cholesterol-free liposomes may
be relevant carriers for agents that are not currently
retained in conventional formulations.
2. Materials and methods
2.1. Lipids and chemicals
Dimyristoylphosphatidylcholine (DMPC), dipal-
mitoylphosphatidylcholine (DPPC) and distearoyl-
phosphatidylcholine (DSPC) lipids were purchased
from Northern Lipids (Vancouver, BC, Canada).
Phosphatidylethanolamine (dimyristoylphosphatidyl-
ethanolamine (DMPE), dipalmitoylphosphatidyl-
ethanolamine (DPPE) and distearoylphosphatidyl-
ethanolamine (DSPE) conjugated polyethylene glycol
lipids were obtained from Avanti Polar Lipids
(Alabaster, AL, USA). HEPES, citric acid, Sephadex
G-50, cholesterol (CH), [14C]lactose and [3H]-choles-
teryl hexadecyl ether (CHE) were obtained from
NEN Life Science Products (Oakville, ON, Canada).
Idamycin (idarubicin hydrochloride for injection) is
manufactured by Pharmacia and Upjohn (Boston,
MA, USA) and obtained from the British Columbia
Cancer Agency.
2.2. Preparation of liposomes
Liposome samples were composed mainly of
DSPC:DSPE-PEG2000 (95:5 mol/mol), DSPC:CH
(55:45 mol/mol) or DSPC:CH:DSPE-PEG2000
(50:45:5 mol/mol/mol). In some studies variations
of these compositions were prepared by altering the
phosphatidylcholine acyl chain length (DPPC or
DMPC), PEG molecular weight (750 and 5000) or
content (2, 10, 15 molar percent). All liposome sam-
ples were prepared by the extrusion technique [34].
Brie£y, lipids were initially dissolved in chloroform
and mixed together in a test tube at the appropriate
mole ratios. [3H]CHE was added as a non-exchange-
able, non-metabolizable lipid marker [35,36]. The
chloroform was evaporated under a stream of nitro-
gen gas and the sample was placed in a high vacuum
overnight. The lipid ¢lms were rehydrated by gentle
mixing and heating in HEPES bu¡ered saline (HBS;
20 mM HEPES, 150 mM NaCl, pH 7.45). The newly
formed multilamellar vesicles (MLVs) were passed 10
times through an extruding apparatus (Northern
Lipids) containing two stacked 100 nm polycarbon-
ate ¢lters. The mean diameter and size distribution of
each liposome preparation, analyzed by a NICOMP
Model 270 Submicron particle sizer (Paci¢c Scien-
ti¢c, Santa Barbara, CA, USA) operating at 632.8
nm, was typically 110 þ 30 nm.
2.3. Lactose trapping
To determine the trapped volume, liposomes were
prepared as mentioned and hydrated in HBS (pH
7.4) containing [14C]lactose (NEN Life Science Prod-
ucts). Following extrusion and sizing, 100 Wl aliquots
were passed down mini Sephadex G-50 spin columns.
Trapped volume was determined by the following
equation:
Trapped volume  A=BC=DUsample volume 1
A = [14C]lactose dpm eluted from spin column;
B = [14C]lactose dpm of initial suspension prior to
gel ¢ltration/100 Wl ; C = [3H]CHE dpm eluted;
D = speci¢c activity of lipid stock (dpm/Wmole total
lipid).
Analysis of [14C]lactose release was determined by
aliquoting 10 mM extruded liposome sample in a
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dialysis membrane (Spectrum Laboratories, Rancho
Dominguez, CA, USA) placed in HBS bu¡er (pH
7.4) solution at 37‡C for 48 h. Aliquots were re-
moved at various time points and run down mini
Sephadex G-50 spin columns.
2.4. Remote loading of idarubicin
The remote loading procedure has been well char-
acterized for weak bases such as anthracyclines, es-
pecially doxorubicin [37]. We have also employed
this technique for the active entrapment of idarubi-
cin. Liposomes were prepared following hydration of
lipid ¢lms in citrate (300 mM citric acid; pH 4.0).
Following extrusion and size determination, lipo-
somes were passed down a Sephadex G-50 column
equilibrated with HBS (pH 7.45) to exchange the
external bu¡er. The resulting liposomes have a trans-
membrane pH gradient, pH 4.0 inside and pH 7.45
outside, and were subsequently stored at 4‡C. On the
day of the experiment liposomes and drug were in-
cubated at de¢ned temperatures in separate test
tubes and subsequently mixed together.
2.5. Time dependent analysis of drug loading
To determine the optimal conditions for drug
loading of IDA in cholesterol-free liposomes at a
0.2 drug to lipid ratio, IDA and liposomes (with an
established pH gradient) were heated at various tem-
peratures (37‡C and 65‡C) for 5 min, mixed together
and placed at the same temperature. At 1, 2, 5, 10,
15, 30, and 60 min post mixing, 100 Wl aliquots were
added to G-50 spin columns (1 ml). Sephadex G-50
spin columns were prepared by adding glass wool to
1 ml syringe and Sephadex G-50 beads packed by
centrifugation (720Ug, 1 min). Following addition
of the sample to the column, the liposome fraction
was collected in the void volume (centrifugation
720Ug, 1 min) and both lipid and drug content
were analyzed. The lipid concentration was measured
by [3H]CHE radioactive counts and IDA was deter-
mined by a spectrophotometric assay at 480 nm. The
spectrophotometric assay consisted of an aliquot of
the eluted sample made up to 100 Wl with deionized
water and 900 Wl 1% Triton X-100. Samples were
heated in boiling water to the cloud point of the
detergent and cooled to room temperature, absor-
bance was measured (Du-64 spectrophotometer,
Beckman) and compared to a standard curve.
2.6. Cryo-transmission electron microscopy
Cholesterol-free liposomes were analyzed by cryo-
transmission electron microscopy (cryo-TEM) and
performed in the laboratory of Dr. Katarina Ed-
wards in Uppsala, Sweden. The method employed
and interpretation of liposome images have been pre-
viously described [38]. Brie£y, in a climate chamber a
drop of the liposome solution was placed on a cop-
per grid containing a polymer ¢lm and blotted, form-
ing a thin aqueous layer on the membrane. The sam-
ple was £ash frozen in ethane allowing the ¢lm to
vitrify, an essential step to prevent crystal formation.
The copper grid containing the sample was trans-
ferred to an electron microscope at liquid nitrogen
temperature where it was analyzed.
2.7. Mice
Female Balb/c mice (6^8 weeks), 20^22 g, breeders
were purchased from Charles River Laboratories (St.
Constant, PC) and bred in house. Mice were housed
in microisolator cages and given free access to water
and food. The room environment was maintained
according to standard operating procedures estab-
lished at the BC Cancer Agency Joint Animal Fa-
cility. All animal studies were conducted according
to procedures approved by the University of British
Columbia’s Animal Care Committee and these stud-
ies were performed in accordance with the current
guidelines established by the Canadian Council of
Animal Care.
2.8. Plasma elimination of liposomes
To determine in vivo drug retention behavior and
circulation longevity, pharmacokinetic studies were
performed. ‘Empty’ or drug loaded [3H]CHE radio-
labeled liposomes were administered intravenously to
the lateral tail vein of Balb/c female mice. Studies
comparing [3H]CHE with radiolabeled [3H]DPPC
were also completed (data not shown) and the results
for the two lipid labels were comparable for choles-
terol-free formulations. The doses of liposomes and
IDA were 165 Wmoles/kg lipid and 33 Wmoles/kg
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IDA, respectively. At various time points post drug
administration, blood was collected by tail nick or
cardiac puncture. The plasma was prepared and a
standard liquid scintillation counting and a standard
extraction assay (see below) determined both lipid
and IDA content, respectively.
The mean area under the curve (AUC) for a de-
¢ned time interval was determined from the concen-
tration^time curves and subsequent calculation by
the standard trapezoidal rule. The plasma data
were modeled using the WinNONLIN Version 1.5
pharmacokinetic software (Pharsight, CA, USA).
2.9. Idarubicin extraction assay
IDA was isolated from plasma in the following
manner. An aliquot of plasma sample was added to
the 16U100 mm test tube and made up to 800 Wl
with distilled water. Subsequently 100 Wl of both
10% SDS and 10 mM H2SO4 were added, vortexed,
and followed by the addition of 2 ml of 1:1 isopro-
panol/chloroform. Samples were placed in 380‡C for
1 h. All tubes were equilibrated to room temperature,
vortexed and centrifuged at 1000Ug for 10 min. The
bottom organic phase was carefully pipetted into a
clean test tube and samples were measured on an LS
50B luminescence spectrometer (Perkin-Elmer, UK)
using an excitation wavelength of 485 (5 nm band-
pass) and an emission wavelength of 535 (10 nm
bandpass) within 30^45 min.
3. Results
3.1. Circulation longevity of cholesterol-free liposomes
Given that the pharmacokinetic behavior of an
encapsulated drug will be dependent on the pharma-
cokinetic characteristics of the drug carrier, studies
were completed to assess circulation longevity of var-
ious liposome formulations. The cholesterol-free
liposome formulation composed of DSPC:DSPE-
PEG2000 (95:5 molar ratio) was compared with
cholesterol-containing formulations consisting of
DSPC:CH (55:45) and DSPC:CH:DSPE-PEG2000
(50:45:5). Each liposome formulation was injected
intravenously into the lateral tail vein of mice and
at various time points aliquots of EDTA prepared
plasma were analyzed to determine total lipid/ml
plasma. As shown in Fig. 1, DSPC liposomes were
rapidly eliminated from the circulation with less than
6% of the injected dose (6 0.2 Wmole/ml plasma)
present at 1 h post administration and an estimated
mean area under the curve (AUC0ÿ24h) of 2.38 Wmole
h/ml. Inclusion of cholesterol into the membrane re-
sulted in a 10-fold increase in the mean AUC0ÿ24h ;
however, at 24 h post administration less than 1% of
the injected dose remained in the plasma compart-
ment. Inclusion of 5 mole% DSPE-PEG2000 into the
DSPC:CH formulation resulted in a 2-fold increase
in the mean AUC in comparison to DSPC:CH
(55:45), a result which is consistent with many other
reports demonstrating that incorporation of PEG
modi¢ed lipids can enhance the circulation lifetime
of liposomes [23]. Inclusion of 5 mole% DSPE-
PEG2000 into DSPC liposomes without cholesterol
engendered signi¢cant increases in circulation life-
times when compared to DSPC formulations without
stabilizing lipids. There was a 19-fold increase in
mean AUC0ÿ24h, and 29% of the injected dose was
present in the circulation after 24 h. This result dem-
onstrated that polyethylene glycol conjugated lipids
are an essential component of cholesterol-free lipo-
Fig. 1. Elimination of cholesterol-free liposomes from the circu-
lation. Large unilamellar liposomes radiolabeled with [3H]CHE
were administered intravenously via the dorsal tail vein of fe-
male Balb/c mice at an approximate dose of 150 Wmoles/kg to-
tal lipid. Blood was collected at 1, 4 and 24 h by tail nick and
cardiac puncture procedures, respectively. An aliquot of plasma
was used to determine liposomal lipid content as described
in Section 2. b, DSPC:DSPE-PEG2000 (95:5 molar ratio);
8, DSPC:CH:DSPE-PEG2000 (50:45:5); 7, DSPC:CH (55:45);
a, DSPC (100). Each data point represents the average lipid
plasma concentration þ S.D. for four mice.
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somes if they are to be used as systemically viable
drug carriers.
While characterizing cholesterol-free liposome for-
mulations it was of importance to decide which for-
mulation would be optimal for application as a de-
livery system for a relatively hydrophobic anticancer
agent, such as IDA. The in£uence of 5 mole% phos-
phatidylethanolamine (PE)-PEG on the plasma elim-
ination of liposomes containing various acyl chain
lengths of phosphatidylcholine, DSPC (C:18),
DPPC (C:16) and DMPC (C:14), was evaluated in
Fig. 2. In these studies the acyl chain length of the
corresponding PE conjugated to PEG contained the
same number of carbons to ensure optimal mixing
conditions; however, it is now well established that
the short chain (C:14 and less) PEG modi¢ed PEs
are rapidly exchanged out of liposomal membranes
after i.v. administration [39,40]. As the acyl chain
length of the phospholipid increased, a more signi¢-
cant di¡erence in circulation longevity between phos-
phatidylcholine (PC) and PC:PE-PEG2000 (95:5)
liposomes was observed. As suggested above, di¡er-
ences in PEG-lipid induced e¡ects on the liposomal
systems may be attributed to the phase state of the
liposomes whereby a more liquid^crystalline phase
lipid may facilitate rapid exchange of lipid compo-
nents out of and into the liposomal membrane fol-
lowing i.v. injection. Although DMPC liposomes ap-
pear to be eliminated at the same rate as
DMPC:DMPE-PEG2000 (95:5) liposomes, upon clos-
er examination we have resolved that DMPC lipo-
somes are not stable, a result that is consistent with
previous observations [41]. Studies evaluating the re-
tention of encapsulated [14C]lactose indicated that
both DMPC and DPPC liposomes lost encapsulated
contents rapidly following injection but DSPC re-
tained entrapped lactose over 48 h (data not shown).
3.2. In£uence of polyethylene glycol content and
molecular weight on cholesterol-free liposome
circulation longevity
Previous studies have demonstrated that the elim-
ination rate of cholesterol-containing systems in-
creases following PEG incorporation, a result that
is dependent on both PEG content and molecular
weight [42^44]. As shown in Figs. 3 and 4, variations
in PEG-lipid content from 2 to 15 mole%, and PEG
molecular weight, from PEG750 to PEG5000, had no
signi¢cant impact on altering the plasma elimination
circulation longevity of DSPC liposomes. It should
be noted that as PEG concentration was increased to
levels in excess of 15 mole% in DSPC liposomes, the
solution became clear indicative of non-liposomal
micelles or bilayer disc formation [45], a result which
is consistent with other reports [46,47]. Furthermore,
in the studies reported here it was established that
the DSPC:PEG2000 formulations with PEG-lipid
content up to 15 mole% existed as a single liposome
population, but the 20 mole% PEG-lipid formulation
existed as two distinct populations as judged by cryo-
TEM analysis and fractionation on Sepharose CL-4B
(data not shown). When using DPPC, incorporation
of 15 mole% PEG resulted in a formulation of a
Fig. 2. Elimination of liposomes prepared using phosphatidyl-
choline species with varying acyl chain lengths in the absence
and presence of PE-PEG2000. Mice were injected with liposomes
as described in Fig. 1. Liposomes of varying acyl chain lengths
DSPC (Panel C), DPPC (Panel B) and DMPC (Panel A) both
in the absence (open symbols) and the presence (closed sym-
bols) of 5 mole% of PE-PEG2000 were evaluated. Each data
point represents the average lipid plasma concentration þ S.D.
for four mice.
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single population of bilayer disks. As suggested by
the data in Fig. 3, even levels of PEG lipid as low as
2 mole% are adequate to maximize the circulation
lifetime of these cholesterol-free formulations.
3.3. Optimal drug loading conditions for idarubicin
The primary purpose of evaluating the pharmaco-
kinetic behavior of the cholesterol-free liposomes was
to determine whether in the absence of cholesterol,
the in vivo retention of drugs poorly retained by
cholesterol-containing formulations could be im-
proved. Since the drug retention attributes of anthra-
cycline derivatives may be correlated to their
hydrophobicity, we chose to assess the use of
DSPC:PEG2000 liposomes to enhance the drug reten-
tion of one of the most hydrophobic anthracyclines,
idarubicin [48]. A liposomal formulation of IDA dis-
playing enhanced drug circulation lifetimes has not
been obtained to date, presumably because the IDA
is rapidly released from cholesterol-containing sys-
tems. The ¢rst step required evaluating the in£uence
of cholesterol on IDA release involved preparation
of drug loaded formulations. The studies described
here have used the well established pH gradient
based loading technique for anthracyclines. In partic-
Fig. 3. Elimination of DSPC liposomes containing increasing
mole% PE-PEG2000. Mice were injected with liposomes as
described in Fig. 1. DSPC liposomes containing 2
(999b999), 5 (999b999), 10 (999a999), and 15
(999a999) mole% PEG were evaluated. Each data point
represents the average total lipid plasma concentration þ S.D.
for four mice.
Fig. 4. Elimination of DSPC liposomes containing varying mo-
lecular weights of 5 mole% DSPE-PEG. Mice were injected
with liposomes as described in Fig. 1. DSPC liposomes contain-
ing 5 mole% DSPE-PEG where the PEG molecular weight was
750 (W W WaW W W), 2000 (999b999) and 5000 (999a999).
Each data point represents the average total lipid plasma con-
centration þ S.D. for four mice.
Fig. 5. Idarubicin loading into liposomes. Liposomes (5 mM)
were incubated with 1 mM idarubicin (drug:lipid ratio 0.2) at
37‡C and 65‡C. At various time points, 100 Wl of the incubat-
ing mixture were run down mini Sephadex G-50 spin columns
and subsequently analyzed for lipid and drug concentrations by
liquid scintillation counting and a standard anthracycline absor-
bance assay as described in Section 2. Drug loading was com-
pared between DSPC:DSPE-PEG2000 (95:5 mol/mol) (b),
DSPC:CH (55:45 mol/mol) (7) and DSPC:CH:DSPE PEG2000
(50:45:5 mol/mol/mol) (8) liposomes.
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ular IDA was loaded at 37‡C and 65‡C into lipo-
somes exhibiting an approx. 3.5 unit transmembrane
pH gradient. As indicated in Fig. 5, IDA displayed
optimal loading in cholesterol-free liposomes at
37‡C. The accumulation of drug into the liposomes
was rapid, with s 95% encapsulation observed in 15
min, after drug addition. In comparison, no di¡er-
ence was observed in DSPC:CH liposomes loading
at 37‡C and 65‡C.
3.4. Evaluation of liposomal idarubicin by
cryo-transmission electron microscopy
Previous studies have explored the structure of
doxorubicin within liposomes, linking the formation
of citrate doxorubicin precipitates to improved reten-
tion [49]. To assess the physical state of encapsulated
IDA, cryo-electron microscopy was used. ‘Empty’
and drug loaded DSPC:DSPE-PEG2000 (95:5 mol/
mol) liposomes were analyzed and the resulting
cryo-TEM images have been summarized in Fig. 6.
As shown by the representative micrographs in Fig. 6
panels A and C, there was an observed di¡erence in
structure between ‘empty’ cholesterol-free and cho-
lesterol-containing liposomes. Several DSPC:DSPE-
PEG2000 (95:5 mol/mol) liposomes within the ¢eld of
view have angular surface features whereas
DSPC:CH:DSPE-PEG2000 (50:45:5 mol/mol/mol)
liposomes consisted primarily as smooth and
rounded membranes. In both cholesterol-free (Fig.
6B) and cholesterol-containing liposomes (Fig. 6D)
with encapsulated IDA, a precipitate was evident in-
side the liposomes, resulting in the ‘co¡ee bean’
structure observed by others for liposomal formula-
tions of doxorubicin. Although these cryo-TEM im-
ages do not eliminate the possibility of IDA interac-
tion with the lipid membrane, it can be concluded
that both cholesterol-containing and cholesterol-free
formulations have some of the entrapped IDA
present as a precipitate in the aqueous core of the
liposome.
3.5. Pharmacokinetic analysis of liposomal idarubicin
Pharmacokinetic studies were performed to deter-
mine the IDA retention attributes of the cholesterol-
Fig. 6. Cryo-transmission electron micrographs of ‘empty’ and idarubicin-containing cholesterol-free and cholesterol-containing lipo-
somes. DSPC:DSPE-PEG2000 (95:5 mol/mol) (A) and DSPC:CH:DSPE-PEG2000 (50:45:5 mol/mol/mol) (C) liposomes were prepared
and cryo-TEM were obtained after establishment of a transmembrane pH gradient, but prior to drug loading. Cryo-electron micro-
graphs of IDA loaded liposomes demonstrated precipitation (see arrows) of idarubicin in cholesterol-free (B) and cholesterol-contain-
ing liposomes (D). Bar represents 100 nm.
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free formulation in vivo. Liposomes were prepared at
a 0.2 drug to lipid ratio and subsequently injected i.v.
into mice at a dose of 165 Wmoles/kg lipid and 33
Wmoles/kg IDA. The plasma elimination pro¢le of
IDA and lipid, as well as the calculated drug to lipid
ratio in the plasma compartment are shown in Fig. 7.
In the absence of a drug carrier, idarubicin is rapidly
eliminated with 6 3% of the injected dose present
after 15 min. This is in sharp contrast to the results
obtained when IDA is administered encapsulated in
DSPC:DSPE PEG2000 (95:5 mol/mol ratio). The
AUC0ÿ4h for free IDA was 0.03 Wmole h/ml in com-
parison to 1.38 Wmole h/ml for cholesterol-free lipo-
somes. The greatest retention of IDA was achieved
using cholesterol-free liposomes, resulting in an
AUC0ÿ4h that was 45-fold higher than for free
IDA. The lipid elimination pro¢les are consistent
with the data shown in Figs. 1 and 2, suggesting
that unlike vincristine and doxorubicin [49,50], IDA
encapsulation does not cause a signi¢cant change in
liposome elimination. The calculated changes in drug
to lipid ratios indicate that the drug retention attrib-
utes of the cholesterol-free formulation are the best
and the data support our contention that cholesterol-
free liposomes provide a format to be used to deliver
drugs not well retained in cholesterol-containing
liposomes.
4. Discussion
These studies have focused on cholesterol-free
liposome delivery systems, with the aim of establish-
ing their utility for delivery of hydrophobic drugs,
such as idarubicin. Prior to establishment of lipo-
some formulations designed for drug delivery appli-
cations [7,13,51,52], cholesterol-free vesicles were the
standard model for biological membranes. Thus
there is a great deal of existing literature on the in
vitro physical and chemical properties of liposomes
prepared without cholesterol. We do believe that this
existing literature provides a solid foundation on
which to support the development of cholesterol-
free liposomes as intravenous delivery systems. De-
spite extensive studies of cholesterol-free formula-
tions, there has been little emphasis on their applica-
tion as drug carriers other than DPPC formulations
being considered as thermosensitive formulations
[53^55]. Others have focused on the physico-chemical
and biological attributes of cholesterol-free lipo-
somes including phase transition temperature deter-
mination by di¡erential scanning calorimetry [47], X-
ray di¡raction [56], and protein binding [57,58], per-
meability [59] and pharmacokinetic studies [19,42].
Collectively these studies provide conclusive evidence
that cholesterol-free liposomes have distinctive prop-
erties that may be bene¢cial for drug carriers. How-
ever, when this information has been applied to
drugs, such as doxorubicin, the cholesterol-free for-
mulation, even when stabilized by PEG-lipid incor-
Fig. 7. Plasma elimination of liposomal idarubicin following i.v.
injection of cholesterol-free and cholesterol-containing lipo-
somes. Large unilamellar liposomes radiolabeled with [3H]CHE
were administered intravenously via the dorsal tail vein of fe-
male Balb/c mice at an approximate dose of 165 Wmoles/kg to-
tal lipid and 33 Wmoles/kg IDA. Blood was collected at 0.25,
0.5, 1, 2 and 4 h. Plasma was prepared and aliquots were as-
sayed for lipid and IDA concentration as described in Section
2. Prolonged circulation longevity of IDA was observed in
DSPC:DSPE-PEG2000 (95:5) (b) in comparison to
DSPC:CH:DSPE-PEG2000 (50:45:5) (8), DSPC:CH (55:45)
(7), and free IDA (E). Each data point represents the average
total lipid plasma concentration þ S.D. for four mice.
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poration, exhibit poor drug retention when com-
pared to cholesterol-containing formulations [55].
We believe that this is due, in part, to the chemical
attributes of the drug used and the phase transition
temperature of DPPC (Tc V39‡C). For a temper-
ature sensitive carrier, it may be advantageous to
select lipids that have a characteristic Tc just above
body temperature, considering that lipids become
more permeable near their phase transition temper-
ature. Therefore selection of lipids with a higher Tc
than 40‡C may facilitate greater retention of en-
trapped solutes. We believe that this report provides,
for the ¢rst time, evidence that cholesterol-free lipo-
somes can exhibit improved drug retention attrib-
utes, thus providing the opportunity to develop
such formulations for drugs that are poorly retained
in cholesterol-containing liposomes.
Within the context of this paper, a direct com-
parison of cholesterol-free DSPC:DSPE-PEG2000
(95:5 mol/mol) liposomes with other successful
drug carrier formulations including conventional
DSPC:CH (55:45 mol/mol) and sterically stabilized
DSPC:CH:DSPE-PEG2000 (50:45:5 mol/mol/mol)
liposomes is provided. There are two important ob-
servations pertaining to cholesterol-free liposomes
that warrant further discussion. First and foremost,
PEG is an essential component of cholesterol-free
liposomes. Its presence engenders enhanced circula-
tion longevity, apparently in a manner that is inde-
pendent of PEG concentration and molecular weight.
Secondly, idarubicin encapsulated in cholesterol-free
liposomes demonstrated greater retention in vivo, in-
dependent of the formation of a precipitate structure
within liposomes.
Our results indicate that DSPC:DSPE-PEG2000
(95:5 mol/mol) liposomes exhibit circulation lifetimes
comparable to sterically stabilized liposome formula-
tions (DSPC:CH:DSPE-PEG2000 ; 50:45:5 mol/mol/
mol). Woodle et al. have also demonstrated that
PEG-PE:PC:CH (1:10:5 molar ratio) and PEG-
PE:PC (0.15:0.85 molar ratio) liposomes exhibited
similar circulation lifetimes, with circulation half-
lives of 15.8 h and 14.9 h, respectively [23]. In the
absence of surface grafted PEGs, cholesterol-free
DSPC liposomes were rapidly eliminated, an obser-
vation that is likely due to either protein binding or
liposome aggregation. As noted during the course of
these studies, both DPPC and DSPC liposomes ag-
gregate rapidly when cooled to a temperature below
the Tc of the acyl chain. In fact, in order to inves-
tigate the properties of pure PC systems, at least 0.5
mole% PEG2000-PE is required. Importantly, the cir-
culation longevity of cholesterol-free DSPC:DSPE-
PEG2000 liposomes following i.v. administration was
not in£uenced by the amount of PEG modi¢ed lipid
(2^15 mole%), or the PEG molecular weight (750^
5000). This is in contrast to previous studies inves-
tigating cholesterol-containing liposomes where PEG
content and molecular weight are important consid-
erations when optimizing the circulation lifetime of
these liposomes [44,60].
In view of the unique observations obtained when
using cholesterol-free liposomes, we postulate that
the incorporation of PEG modi¢ed lipid is primarily
responsible for minimizing liposome^liposome aggre-
gation, although we cannot be certain that the sur-
face grafted PEGs inhibit protein binding and this
e¡ect may be di¡erent when considering their behav-
ior in cholesterol-free as compared to cholesterol-
containing liposomes. Others have demonstrated
that cholesterol is required to maintain stability of
liposomes in the plasma compartment [7,13,51,61].
Many of these studies were completed with small
unilamellar liposomes prepared using lipids that ex-
hibited Tc below 37‡C, and thus were likely in a £uid
phase when injected into mammals. Bedu-Addo et al.
and others have demonstrated that cholesterol-free
liposomes exhibit a phase transition temperature
[47], but this transition broadens and becomes di⁄-
cult to measure when the cholesterol level increases
[62]. When using liposomes prepared of de¢ned acyl
length PCs, heating them above the phase transition
temperature and subsequent cooling them below the
Tc causes membrane defects (grain boundaries) to
form. The appearance of defects is clearly evident
in the cryo-TEM shown in Fig. 6 and these mem-
brane defects are believed to be the source of non-
speci¢c protein binding [61] which, in turn, may de-
¢ne whether the carrier is recognized by the cells of
the MPS system. Addition of surface stabilizing com-
pounds such as PEG may shield these defects from
recognition by serum proteins, rendering them more
stable than liposomes composed exclusively of satu-
rated phospholipids. An inherent attribute of such a
conclusion is that pure PC liposomes may display
reduced protein binding attributes provided that the
BBAMEM 78225 26-4-02
N. Dos Santos et al. / Biochimica et Biophysica Acta 1561 (2002) 188^201 197
membrane defects are shielded by PEGs. Our results
suggest that this can be achieved for a broad range of
PEG molecular weight species and surface grafting
densities.
The entrapment of idarubicin into cholesterol-free
DSPC:DSPE-PEG2000 liposomes with an estab-
lished pH gradient proved to be as e¡ective with
cholesterol-free liposomes when compared to choles-
terol-containing formulations. As expected, how-
ever, the drug loading attributes of the cholesterol-
free formulation were more dependent on the tem-
perature used for loading and IDA could not be
encapsulated at 65‡C in cholesterol-free liposomes,
a temperature higher than its phase transition tem-
perature. Similarly, Unezaki et al. loaded thermo-
sensitive (cholesterol-free) DSPC:DPPC:DSPE-
PEG (1:9:0.61 molar ratio) liposomes with doxoru-
bicin by the remote loading procedure at 60‡C for
10 min and only achieved 65% encapsulation e⁄-
ciency. Reduced loading may be a consequence of
membrane destabilization at temperatures above the
Tc of the bulk membrane component. Our studies
demonstrated that s 95% IDA was loaded into the
PEG-PE stabilized DSPC liposomes at 37‡C. The
ability to load IDA into liposomes at a lower tem-
perature than the phase transition temperature may
be directly attributed to IDA’s hydrophobicity [63].
Consistent with cholesterol-containing liposomes,
drug loading for the cholesterol-free liposomes is
dependent on liposome composition as well as the
speci¢c physico-chemical properties of the drug
being used. Importantly, the cholesterol-free formu-
lations may be particularly well suited for the more
hydrophobic drugs. Woodle et al. hypothesized that
by adding PEG to a membrane, one could eliminate
the requirement of lipids with high phase transition
temperature to allow greater control of leakage rates
and other important bilayer properties [23]. Remov-
ing cholesterol from the membrane may facilitate
even greater £exibility and control of drug leakage
rates, when combined with the stabilization e¡ects
of PEGs.
Upon drug loading cryo-TEM images indicated
that IDA was present in a precipitated form. This
observation is consistent with other anthracyclines
that have been encapsulated in liposomes by loading
methods relying on the use of encapsulated citrate or
ammonium sulfate [64]. It is interesting that Gallois
et al. have speci¢cally studied IDA’s interaction with
phospholipid membranes concluding that IDA em-
beds within the bilayer forming a complex with
phosphatidic acid and cholesterol [65]. Considering
that neither cholesterol nor phosphatidic acid are
present within our liposomes, the remote loading
procedure allows IDA to be present at concentra-
tions high enough for the anthracyclines to stack
and self-associate [49]. Self-association may be
more energetically favorable than interactions depen-
dent on membrane partitioning, although the mem-
brane partitioning behavior of IDA may play a di-
rect role in enhancing the drug retention attributes
observed here for DSPC:PEG-PE formulations. As
shown clearly in Fig. 6, IDA was present in a pre-
cipitated form within cholesterol-containing lipo-
somes, as well as cholesterol-free liposomes. This
result suggests that enhanced retention within cho-
lesterol-free liposomes was not solely a consequence
of precipitate formation. Our studies demonstrated
that membrane composition also governs drug re-
lease kinetics, and we continue to believe that the
most important factor governing the release charac-
teristics of a liposomally encapsulated drug is lipid
composition. As modeled in Fig. 8, the release of
entrapped idarubicin (present in both free and pre-
cipitated forms) from the aqueous core of a liposome
to the external environment is dependent on the par-
titioning behavior of the drug. This, in turn, is de-
pendent on pH, membrane surface charge and the
chemical attributes of the lipid acyl chains. Although
our initial rationale for employing cholesterol-free
liposomes for retention was simple, our model sug-
gests that release due to interaction of the drug with
components of the liposome is complex. For exam-
ple, the chemical reaction used to prepare PEG
modi¢ed phospholipids results in the generation of
an anionic lipid from a zwitterionic lipid. The pres-
ence of this charged lipid will in£uence drug release
properties, as noted by others [66], and this is pre-
sumably due to enhanced partitioning of the encap-
sulated drug. Drug partitioning behavior will be de-
pendent on a number of processes which are
dictated, in part, by the equilibrium between proton-
ated and unprotonated drug forms as they transfer
from the precipitated complex trapped in the core of
the liposome (see Fig. 6) through the bilayer inter-
face and the bilayer itself. Although we have not
BBAMEM 78225 26-4-02
N. Dos Santos et al. / Biochimica et Biophysica Acta 1561 (2002) 188^201198
investigated the degree of partitioning of IDA within
cholesterol-free and cholesterol-containing lipo-
somes, we believe that membrane interactions are
the most critical determinant of drug release.
In conclusion, we have demonstrated that choles-
terol-free liposomes with surface grafted PEG may
have unforeseen advantages over cholesterol-contain-
ing formulations. Inclusion of surface stabilizing
components such as PEG eliminates the requirement
of cholesterol within a membrane that exhibits very
di¡erent drug release properties. In our case, we
achieved enhanced retention of idarubicin, a hydro-
phobic agent readily released from conventional for-
mulations. Future studies will focus on investigating
drug release kinetics by altering loading parameters
and PEG chemistry. In addition we will assess
whether altering circulation longevity of IDA will
impact the pharmacological properties of the drug
in preclinical tumor models.
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